{"id":"NCT01705145","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation","officialTitle":"A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2012-10-12","resultsPosted":"2015-04-24","lastUpdate":"2016-04-05"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["Kalydeco","VX-770"]}],"arms":[{"label":"Ivacaftor","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), of ivacaftor in children with cystic fibrosis (CF) who are 2 through 5 years of age and have a CF Transmembrane Conductance Regulator (CFTR) gating mutation in at least 1 allele.\n\nPart A is designed to evaluate the safety and PK of multiple-dose administration of ivacaftor in participants 2 through 5 years of age and to confirm the doses for Part B. Part B is designed to evaluate the safety, PK, PD, and efficacy of ivacaftor in participants 2 through 5 years of age.","primaryOutcome":{"measure":"Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs","timeFrame":"Part A: Up to 93 Days","effectByArm":[{"arm":"Part A: Ivacaftor 50 mg","deltaMin":3,"sd":null},{"arm":"Part A: Ivacaftor 75 mg","deltaMin":5,"sd":null},{"arm":"Part A: Overall Ivacaftor","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":20,"countries":["United States","Canada","United Kingdom"]},"refs":{"pmids":["26803277"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["Cough","Vomiting","Pyrexia","Nasal congestion","Rhinorrhoea"]}}